What’s the Evidence for HTA?
In this blog, Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate, explains NICE’s role as co-host of [...]
Amazon, Apple, Facebook, and Google Target the Health Insurance Market
According to a recent analysis and report published by CB Insights, Amazon, Apple, Facebook, and Google have been able to [...]
The Shifting Evidence Landscape in the Era of COVID-19
There is extreme pressure on governments, researchers, and health care providers to deliver effective, evidence-based approaches to the prevention, detection, [...]
What Post-pandemic changes Would Patients Like to See Continue?
CoverMyMeds recently performed a patient survey which also heavily informed the COVID-19 & Medication Access report. In the survey, patients [...]
[Webinar] Patient-Focused Medicines Development During COVID-19
The COVID-19 pandemic has turned the lives of many patients upside down by adding additional layers of complexity. How exactly [...]
[Virtual Seminar] Statistics for the Non-Statistician
Join Steven Wachs on Thursday, October 15, 2020 at 11:00 AM EDT for a 6-Hour Virtual Seminar on Statistics for [...]
Ethnoracial Disparities Pervasive in Clinical Research
As clinical trials are the gold standard for evidence-based medicine, it is essential for researchers to be as inclusive as [...]
Researchers Perform Integrative Review of Managed Entry Agreements
Managed entry agreements (MEAs) are of group of instruments designed to reduce the budget impact, uncertainty, and risk of expensive [...]
What COVID-19 Can Teach Us About Real World Data
Due to the urgent need to characterize and track the spread of COVID-19, good healthcare data have been highly sought [...]
WHO’s New Pricing Policy Guideline Makes Medicines More Affordable
A new WHO guideline aims to help governments overcome the barrier of high prices for pharma products, enabling them to [...]
[Webinar] Bayesian Statistics and FDA Regulatory Acceptability
Bayesian statistics have been used in regulatory submissions to the Food and Drug Administration (FDA) for over 15 years in [...]
Size Doesn’t Matter: A Small Biotech Plays Big with Payer Engagement
Last month, Dr. Patti Peeples, CEO of HealthEconomics.Com, interviewed Allen Lising on how Xcenda’s FormularyDecisions™ is used early in drug development [...]
[Webinar] Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient-Centered?
Researchers, value assessors, and the patient community agree that traditional means of value assessment often do not factor in the [...]
Geographic Bias Present in Medical AI Tools
Historically, diversity has not been a serious consideration in the minds of researchers when studying new medications. Most clinical trials [...]
How Can Specialty Pharmacy Thrive in the New Era of Value?
The days of fee-for-service health care are coming to an end, with value-based initiatives that improve patient outcomes, reduce cost, [...]
CADTH Resumes Scientific Advice Activities
CADTH just announced that they have resumed activities in their Scientific Advice Program and are once again accepting applications for [...]
NICE Seeks to Simplify Selection Process for Drug and Medical Device Evaluation
NICE is seeking public input on changing the process it uses to selects the topics it develops guidance on. The [...]
The Trouble With List Prices
This week, the RAND Corporation issued a new report highlighting that US list prices on insulin are 8.1 times higher than [...]
ICER Launches Customizable COVID-19 Cost-Effectiveness Model
The Institute for Clinical and Economic Review (ICER) announced the launch of a cloud-based platform that allows customization of model [...]
ConcertAI Launches CancerLinQ, An Oncology-focused Set of COVID-19 Resources
ConcertAI recently launched CancerLinQ Discovery, a set of oncology-focused COVID-19 resources aimed at supporting the needs of providers, innovators, and [...]
AstraZeneca Walks Back On its COVID-19 ‘No-Profit’ Pledge
Among the many pharma companies racing to develop a safe, effective vaccine for COVID-19, AstraZeneca stands out for its pledge [...]
Increasing Transparency in HEOR Through the Real-World Evidence (RWE) Transparency Initiative
Due to the funding or execution of studies by industry stakeholders and disagreements over methodological approaches, establishing and maintaining trust [...]
Dr. William Morice on Applying RWE to COVID-19 diagnostics
One of the most critical pieces of the COVID-19 puzzle is diagnostic testing that enables rapid diagnosis and treatment of [...]
PCORI’s Research Scope Expanded to Include Cost Outcomes
The Patient-Centered Outcomes Research Institute (PCORI) was created by the Affordable Care Act (ACA) in 2010. Since then, the institute [...]
Access Market Intelligence’s Specialty Pharmacy Database Now Available
Access Market Intelligence recently released its Specialty Pharmacy Database (SPD) which provides the industry’s most comprehensive, continually updated database on [...]